Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact

Archives

Monthly Archive for: "Dicembre, 2022"
Home » Archivi per Dicembre 2022
 0

Dr. Marina Udier comments the Neoantigen vaccine report card issued by BioCentury

Please find the full report below:

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!